Full Press Release Details
Powered and protected by
Privacy
ONC Neutral Sentiment Score: 50/100
BeOne présente des données historiques de phase 3 chez des patients atteints de LLC âgés de 80 ans et plus lors du congrès EHA 2026, confirmant ainsi les bénéfices de BRUKINSA
Key Takeaway: BeOne presented historical Phase 3 data at the EHA 2026 congress, focusing on patients aged 80 and older with chronic lymphocytic leukemia (CLL). The data confirmed the benefits of BRUKINSA in this demographic. The presentation highlights the ongoing research and development efforts in treating CLL among elderly patients.
Market Sentiment Analysis
Frequently Asked Questions
What data did BeOne present at EHA 2026?
BeOne presented historical Phase 3 data on BRUKINSA for elderly CLL patients.
Who were the patients in the BeOne study?
The study focused on patients aged 80 years and older with chronic lymphocytic leukemia.
What is BRUKINSA used for?
BRUKINSA is used for treating chronic lymphocytic leukemia (CLL).
What was the significance of the EHA 2026 presentation?
The presentation confirmed the benefits of BRUKINSA in elderly patients with CLL.